Atea Pharmaceuticals, Inc. - common stock — Cash Flow (NASDAQ:AVIR) | MetaTrader

Open full chart Full chart

Financials

Overview Statement Statistics

Quarterly Annual

Cash from operating activities 296.73 M-87 M-120.98 M-85.39 M-135.5 M-132.03 M -147.86 M Cash from investing activities -26 K-4 000-455.41 M40.3 M56.1 M188.79 M 132.92 M Cash from financing activities 531.75 M1.47 M370 K257 K267 K-25.75 M -25.14 M Free cash flow 296.73 M-87 M-120.98 M-85.39 M-135.5 M-132.03 M -147.86 M

News

Atea Pharmaceuticals - I'm Optimistic Ahead Of Critical HPV Catalyst (NASDAQ:AVIR)

Down 25% in 4 Weeks, Here's Why Atea Pharmaceuticals (AVIR) Looks Ripe for a Turnaround

Atea Pharmaceuticals, Inc. (AVIR) Q1 2026 Earnings Call Transcript

Atea Pharmaceuticals, Inc. 2026 Q1 - Results - Earnings Call Presentation (NASDAQ:AVIR) 2026-05-12

Top 2 Health Care Stocks That May Fall Off A Cliff This Month - Arcellx (NASDAQ:ACLX), Atea Pharmaceuticals (NASDAQ:AVIR)

Atea Pharmaceuticals, Inc. 2025 Q4 - Results - Earnings Call Presentation (NASDAQ:AVIR) 2026-03-05

Atea Pharmaceuticals, Inc. (AVIR) Q4 2025 Earnings Call Transcript

Atea Q4 2025 slides: pivotal HCV Phase 3 data due mid-2026

Earnings call transcript: Atea Pharmaceuticals Q4 2025 sees stock rise despite EPS miss

Atea Pharmaceuticals, Inc. (AVIR) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow (NASDAQ:AVIR) 2026-01-19

Atea Pharmaceuticals, Inc. (AVIR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Atea’s HCV treatment regimen phase 3 results expected mid-2026